Literature DB >> 15613017

Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia.

J I Zwicker1, L Uhl, W-Y Huang, B H Shaz, K A Bauer.   

Abstract

The natural history of heparin-induced thrombocytopenia (HIT) in the absence of thrombosis was previously established using functional assays for confirmation of diagnosis (e.g. 14C serotonin release assay). An enzyme-linked immunosorbent assay (ELISA) that detects the presence of antibodies directed against the heparin-platelet factor-4 (PF4) complex has largely replaced functional assays in many medical centers. Although the ELISA is highly sensitive for detecting HIT antibodies, its usefulness for predicting thrombotic outcomes has not been clearly established. We performed a retrospective chart review of all hospitalized patients at a university hospital who tested seropositive for HIT by a commercial ELISA during 2001 and 2002. A total of 63 inpatients were identified as HIT positive by ELISA. Forty-eight patients had no apparent HIT-associated thrombosis at the time of HIT seropositivity (i.e. isolated HIT) and only one was treated prophylactically with a direct thrombin inhibitor. The 30-day thrombosis rate for patients with isolated HIT was 17% (eight of 48). Higher ELISA optical density (OD) measurements correlated significantly with thrombosis (1.41 +/- 0.87 vs. 0.79 +/- 0.46, P <0.001). Patients with isolated HIT and an OD measurement of > or = 1.0 demonstrated nearly a 6-fold increased risk of thrombosis compared with those with OD values between 0.4 and 0.99 (odds ratio 5.74, 95% confidence interval 1.73, 19.0; absolute rate of thrombosis, 36% vs. 9%, respectively, P=0.07). We conclude that in hospitalized patients with isolated HIT, the presence of heparin-PF4 antibodies detected by ELISA was associated with a significant risk of subsequent thrombosis and higher ELISA values were observed among patients suffering thrombotic events.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15613017     DOI: 10.1111/j.1538-7836.2004.01039.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  43 in total

1.  Improving the specificity of the PF4 ELISA in diagnosing heparin-induced thrombocytopenia.

Authors:  Janice McFarland; Andrew Lochowicz; Richard Aster; Bryan Chappell; Brian Curtis
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

2.  Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia.

Authors:  Nicole L Whitlatch; David F Kong; Ara D Metjian; Gowthami M Arepally; Thomas L Ortel
Journal:  Blood       Date:  2010-05-27       Impact factor: 22.113

Review 3.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 4.  Heparin-induced thrombocytopenia.

Authors:  Grace M Lee; Gowthami M Arepally
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

5.  Canadian consensus recommendations on the management of venous thromboembolism in patients with cancer. Part 2: treatment.

Authors:  J C Easaw; M A Shea-Budgell; C M J Wu; P M Czaykowski; J Kassis; B Kuehl; H J Lim; M MacNeil; D Martinusen; P A McFarlane; E Meek; O Moodley; S Shivakumar; V Tagalakis; S Welch; P Kavan
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

6.  Optical density values correlate with the clinical probability of heparin induced thrombocytopenia.

Authors:  Brendan M Weiss; Nathan M Shumway; Robin S Howard; Lloyd K Ketchum; Thomas J Reid
Journal:  J Thromb Thrombolysis       Date:  2007-11-04       Impact factor: 2.300

7.  High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass.

Authors:  Grace M Lee; Ian J Welsby; Barbara Phillips-Bute; Thomas L Ortel; Gowthami M Arepally
Journal:  Blood       Date:  2013-02-19       Impact factor: 22.113

Review 8.  Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician.

Authors:  Connie N Hess; Richard C Becker; John H Alexander; Renato D Lopes
Journal:  J Thromb Thrombolysis       Date:  2012-11       Impact factor: 2.300

Review 9.  Heparin-induced thrombocytopenia.

Authors:  Gowthami M Arepally; Thomas L Ortel
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

10.  A comparison of direct thrombin inhibitors in the treatment of Heparin-Induced Thrombocytopenia: a single institution experience.

Authors:  Karen M Curzio; A Cheng-Lai; V Kheyfets; M Sinnet; H H Billett
Journal:  J Thromb Thrombolysis       Date:  2008-09-25       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.